Maxidus capsules

Safety advisory

8 September 2011

The Therapeutic Goods Administration (TGA) is aware that some Australian consumers may have purchased the product Maxidus capsules over the internet. The label of this product claims the ingredients to be a herbal supplement.

However, analysis undertaken by the TGA Laboratories in Australia has confirmed the presence of sulfohydroxyhomosildenafil in the capsules.

Sulfohydroxyhomosildenafil is considered to be a derivative of Sildenafil, the active ingredient in the approved Pfizer Australia Pty Ltd product Viagra, which is indicated for the treatment of male erectile dysfunction.

Consumers are advised that sulfohydroxyhomosildenafil is a prescription-only medicine in Australia, and may be harmful if taken without the supervision of a medical professional, particularly in patients with history of cardiovascular disease.

Maxidus capsules have not been assessed by the TGA for quality, safety or efficacy as required under Australian legislation, and the place of manufacture is not approved by the TGA. In Australia, the importation and supply of Maxidus capsules is illegal.

If you have purchased Maxidus capsules you are advised to cease using them and discard any remaining product. If you have concerns arising from your use of this product, you should consult your health care practitioner.

Consumers are again advised to exercise extreme caution about purchasing medicines from unknown overseas internet sites. Products purchased in this way may not meet the same standards of quality, safety and efficacy as those approved by the TGA for supply in Australia, and may contain undisclosed and potentially harmful ingredients.

Maxidus capsules and packaging